Clinical Features and Prognosis of Patients With Coronary Spasm–Induced Non–ST‐Segment Elevation Acute Coronary Syndrome

Naoki Nakayama(Kumamoto University), Hisao Ogawa(Jikei University School of Medicine), Kenichi Tsujita(British Heart Foundation), Koji Sato(Kumamoto University), Kazuo Kimura(Kazan State Medical University), Yasushi Matsuzawa(Yokohama City University Medical Center), Tomohiro Sakamoto(Kumamoto University), Seiji Hokimoto(Omuta hospital), Sunao Kojima(Kumamoto University), Seigo Sugiyama(Kumamoto University), Eiji Horio(Kumamoto University), Koichi Kaikita(Kumamoto University), Kōichi Nakao(Saiseikai Kumamoto Hospital), Michio Mizobe(Kumamoto University), Hiromi Yoshimura(Kumamoto University), Takashi Fukunaga(Saiseikai Kumamoto Hospital), Shinji Tayama(Saiseikai Kumamoto Hospital), Seiji Takashio(Kumamoto University)
Journal of the American Heart Association
May 9, 2014
10.1161/jaha.114.000795
Cited by 58

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
|JAMA|2019|830
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753